For Accredited Investors Only · Confidential · Not an Offer or Solicitation
Team & Advisers

Experience Across Science, Operations & Transactions

Aether's general partners combine scientific asset development, clinical diligence, healthcare M&A, investment management, and capital formation to evaluate opportunities across therapeutic innovation and the businesses that support its development and delivery.

General Partners

One Mandate Each, One Shared Strategy

Elizabeth Parrish, MBA

Elizabeth Parrish, MBA

General Partner
Science & Asset Strategy

Elizabeth Parrish leads Aether's Science & Asset Strategy, focusing on biotechnology opportunity sourcing, scientific differentiation, and asset-development priorities. As BioViva's founder and CEO and a named gene-therapy patent inventor, she brings experience building investigational programs for age-related disease. Her role connects the fund's innovation strategy with the scientific expertise, development capabilities, and partnerships needed to evaluate and advance promising therapeutic platforms.

Tucson Dunn

Tucson Dunn

General Partner
M&A, Integration & Operations

Tucson Dunn leads Aether's M&A, Integration & Operations, bringing international healthcare transaction and operating experience to the fund's acquisition strategy. His background includes healthcare M&A at Fosun, hospital-division leadership at Medicover, and multi-site operational transformation. He focuses on a target's operating quality, integration requirements, and improvement opportunities, connecting acquisition assessment with the management and execution needed to develop the business after investment.

Eugene Durenard, PhD

Eugene Durenard, PhD

General Partner
Fund Structure & Investment Strategy

Eugene Durenard leads Aether's Fund Structure & Investment Strategy, drawing on institutional asset management, healthcare investing, and family-office advisory experience. A co-founder of Orion Investment Management with chief investment officer experience at Healthcare Impact Holdings, he focuses on fund architecture, capital allocation, and portfolio construction. His role connects the merits of individual opportunities with their financing requirements, development timelines, risks, and fit within Aether's overall strategy.

Jordan Dawson, PharmD, BCCCP

Jordan Dawson, PharmD, BCCCP

General Partner
Clinical Strategy & Portfolio Development

Jordan Dawson leads Aether's Clinical Strategy & Portfolio Development, combining healthcare opportunity sourcing with clinical and translational diligence, evidence strategy, and portfolio oversight. Her experience in pharmaceutical medical affairs, healthcare acquisition diligence, and clinical leadership informs the assessment of scientific credibility, therapeutic differentiation, and adoption potential. She also evaluates the clinical and operating capabilities that healthcare businesses can contribute to Aether's broader innovation and commercialization strategy.

Daniel Passarelli

Daniel Passarelli

General Partner
Capital Formation & Investor Relations

Daniel Passarelli leads Aether's Capital Formation & Investor Relations, focusing on investor development, capital relationships, and financing coordination. His experience at Dominus Capital Group includes acquisition origination, capital sourcing, and equity-partnership strategies. Combined with healthcare business ownership, that background informs his work connecting Aether's investment thesis and capital requirements with prospective investors whose objectives and investment horizons fit the fund's strategy.

Advisory Board · AI Implementation

AI Strategy & Implementation

Aether applies AI across the fund's plan and portfolio operations — guided by a dedicated implementation advisor.

Daniel Reynoso — former SpaceX, founder of My Horizon

Daniel Reynoso

Advisory Board — AI Implementation

Founder of My Horizon, where the team develops AI-enabled software and business automation. A former SpaceX team member, his work spans AI agent systems (Synthios), collaboration on Tool Savants' Pocket Marketer, acquisition research, and decision-support tools — connecting business information, automating repetitive workflows, and keeping key decisions under human review.

Daniel advises Aether on applying AI across the fund's plan and portfolio operations, translating emerging capabilities into practical tools for owners, operators and their teams.

Advisers / Asset Leadership

Scientific & Clinical Advisers

DC

Diana Castro, MD

Clinical Adviser
SJ

Sheldon Jordan, MD, FAAN

Neurology Adviser
BA

Bill Andrews, PhD

Science Adviser
Request Access to the Data Room

Important information. Confidential discussion material for accredited investors only; not an offer or solicitation. Team and adviser roles are described for context and are subject to definitive documentation. Nothing here is a performance representation, promise or guarantee.

Elizabeth Parrish, MBA

General Partner · Science & Asset Strategy

Elizabeth Parrish leads Science & Asset Strategy at Aether Longevity Fund, focusing on the identification and development of biotechnology opportunities relevant to longevity and age-related disease. Her role spans scientific opportunity sourcing, therapeutic-platform assessment, and asset-development priorities, helping the fund evaluate where a differentiated biological approach could support a compelling investment thesis.

As the founder and chief executive officer of BioViva, Elizabeth has built a biotechnology company pursuing investigational gene therapies directed at age-related conditions. Her experience includes therapeutic-platform development, scientific collaboration, and intellectual-property development. She is a named co-inventor on a U.S. patent concerning viral-vector approaches to age-related cognitive decline, bringing direct experience with the relationship between a therapeutic concept, its underlying intellectual property, and an asset-development strategy.

That company-building background informs her work at Aether: assessing what distinguishes a platform, the maturity of its development program, and the scientific capabilities and partnerships needed for its next stage. Her relationships across biotechnology and regenerative medicine support engagement with founders and scientific teams, adding a sector-focused sourcing perspective to the fund's evaluation of emerging opportunities.

Elizabeth works with Aether's clinical, investment, and operating partners to connect scientific assessment with evidence requirements, development planning, and commercial potential. Her contribution is particularly relevant to the fund's strategy of pairing therapeutic innovation with the manufacturing and clinical-translation capabilities needed to advance it. She focuses on identifying assets with a clear scientific rationale and defining the priorities, expertise, and partnerships required to test that rationale through development.

Tucson Dunn

General Partner · M&A, Integration & Operations

Tucson Dunn leads M&A, Integration & Operations at Aether Longevity Fund, applying healthcare acquisition and executive operating experience to the evaluation and development of healthcare businesses. His role connects the fund's acquisition strategy with the practical work of assessing management, financial performance, service delivery, and integration requirements before committing capital.

As Managing Director of International Healthcare at Fosun Healthcare Holdings, Tucson led healthcare M&A investment activity across Europe and Asia, including hospitals, clinics, laboratories, and pharmacy chains. He also led Medicover's Hospitals Division during preparation for the group's initial public offering. These roles bring directly relevant experience in evaluating healthcare businesses and managing the operational and organizational demands of multi-site providers.

His broader career includes more than three decades of international healthcare leadership, hospital turnarounds, and clinical and financial transformation. In a Chief Transformation Officer consulting engagement with Hoan My Medical Corporation, he focused on clinical excellence, resource utilization, and operational redesign across a multi-hospital organization. Executive work in biotechnology, including cell-based therapy programs at SMC and JLM ExoGrade, adds experience with businesses whose operating needs are shaped by research and clinical development.

At Aether, Tucson uses that combination to assess both the quality of an acquisition target and the work required to improve it. His focus includes management capability, clinical and operational controls, service economics, integration planning, and opportunities for greater operating efficiency. He works alongside the fund's clinical and investment partners to connect each acquisition thesis with a practical operating plan, supporting Aether's strategy of building healthcare businesses and capabilities that complement its therapeutic investments.

Eugene Durenard, PhD

General Partner · Fund Structure & Investment Strategy

Eugene Durenard leads Fund Structure & Investment Strategy at Aether Longevity Fund, bringing institutional investment-management and healthcare-investing experience to fund architecture, capital allocation, and portfolio construction. His work focuses on how individual opportunities contribute to the overall strategy, considering their financing requirements, development timelines, risk exposure, and potential sources of value.

Eugene co-founded Orion Investment Management, an institutional asset manager in Bermuda, and subsequently co-headed the acquiring group's asset-management business following Orion's sale to Capital G. His earlier work at Salomon Brothers and Credit Suisse, together with his PhD in Mathematics from Harvard University, provides a quantitative foundation for evaluating investment assumptions, portfolio risk, and capital allocation rather than assessing each opportunity in isolation.

His healthcare investment background includes founding Hyperbolic Holdings and co-founding Healthcare Impact Holdings, where he served as chief investment officer with a focus on later-stage private healthcare ventures. He has advised family offices on direct life-sciences investments and served on the board of Co-Diagnostics, including as audit committee chair. That experience brings healthcare opportunity assessment, investor perspective, and financial oversight to Aether's investment process.

Within Aether's strategy, Eugene's role is to connect therapeutic investments and healthcare operating businesses within a coherent portfolio. He works with the scientific, clinical, and operating partners to translate asset-level diligence into investment sizing, financing plans, reserve requirements, and portfolio priorities. His focus is on aligning capital with the evidence and operating milestones required to advance each investment, while evaluating how different development horizons and business models affect the fund as a whole.

Jordan Dawson, PharmD, BCCCP

General Partner · Clinical Strategy & Portfolio Development

Jordan Dawson leads Clinical Strategy & Portfolio Development at Aether Longevity Fund, with responsibility for healthcare opportunity sourcing, clinical and translational diligence, evidence strategy, and portfolio oversight. She evaluates how a therapy's scientific rationale, clinical data, and delivery model translate into an investable opportunity, and how healthcare businesses can support the fund's broader innovation and commercialization strategy.

Her pharmaceutical medical affairs experience in neurology and rare disease includes work with ALS and Parkinson's disease programs, clinical-trial investigators, and specialist physicians. She has supported development-stage scientific exchange, clinical-trial site engagement, and launch readiness. This experience informs her assessment of unmet clinical need, therapeutic differentiation, evidence quality, and the practical requirements for physician adoption, particularly in neurodegeneration and other areas relevant to longevity. These clinician and investigator relationships also inform her approach to healthcare opportunity sourcing.

Jordan has also conducted clinical and operational diligence on acquisition targets in longevity, regenerative medicine, and telehealth. Her work has included assessing mechanism-of-action claims, safety evidence, clinical protocols, supplier capabilities, care-delivery workflows, and unit economics, then translating those findings into acquisition evaluations and integration recommendations. Having founded and operated a telehealth business, she brings practical experience with the infrastructure and execution needed to turn a clinical offering into an operating service.

Earlier leadership roles at Denver Health and UCHealth involved evaluating therapies for institutional use, developing clinical protocols, and assessing pharmacoeconomic value. That background supports Aether's evaluation of both clinical utility and the economics of healthcare delivery. Across sourcing and portfolio development, Jordan focuses on identifying evidence gaps, shaping clinical and real-world evidence priorities, and connecting scientific evidence with a credible path to adoption. She holds a PharmD from the University of Colorado and board certification in critical care pharmacy.

Daniel Passarelli

General Partner · Capital Formation & Investor Relations

Daniel Passarelli leads Capital Formation & Investor Relations at Aether Longevity Fund, with a focus on developing investor relationships and coordinating capital around the fund's investment strategy. His role connects Aether's scientific and operating investment thesis with prospective capital partners, translating the portfolio's objectives, financing needs, and development horizons into focused investor discussions.

As chief executive officer of Dominus Capital Group, Daniel's work spans acquisition origination, capital sourcing, and financing strategies for operating businesses and other assets. His experience includes evaluating acquisition opportunities, working with business owners and capital providers, and developing equity-partnership and growth-financing approaches. These activities are directly relevant to understanding how an investment opportunity is presented, how financing requirements are assessed, and how relationships between operators and capital partners are developed.

His healthcare business experience includes ownership of Focal Point Vitality and work on acquisition and expansion opportunities involving regenerative medicine and telehealth. This adds an operating-business perspective to Aether's capital-formation function: an understanding of the commercial requirements behind a healthcare growth plan, rather than viewing capital raising separately from the business it is intended to support.

At Aether, Daniel works with the investment, scientific, clinical, and operating partners to communicate the fund's strategy, coordinate investor diligence, and support financing discussions. He focuses on developing relationships with investors whose objectives and time horizons align with Aether's combination of therapeutic innovation and healthcare operating businesses. His contribution is to connect the fund's capital-development efforts with the requirements of its investment plan and maintain a clear dialogue between the GP team and prospective investors.